Effect of the docetaxel (TXT)-cisplatin (CDDP) therapy in patients with CAF resistant recurrent (metastatic) breast cancer

Japanese Journal of Clinical Radiology

Volumn 45, Issue 13, 2000, Pages 1643-1647

  Kariya, S ^a   Ogawa, Y ^a   Nishioka, A ^a   Terashima, M ^a   Yoshida, S ^a   Inomata, T ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; NAVELBINE; PACLITAXEL; TAMOXIFEN;

ADULT; ANOREXIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEMALE; HUMAN; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PARTIAL MASTECTOMY; RECURRENT CANCER;

EID: 0034533946     PISSN: 00099252     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group
2. Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients; the French compassionate use programme experience
3. 2 is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-A phase II single-center study
4. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure; a randomised phase III study with crossover on progression by the Scandinavian Breast Group
5. An improved synthesis of the Taxol side chain and of RP56976
6. Studies with RP56976 (Taxotere); a semisynthetic analogue of Taxol
7. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer
8. Docetaxel (T) and cisplatin (P) in anthracycline-pretreated advanced breast cancer (ABC); results of a phase II pilot study
9. Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant breast cancer
10. Taxotere (T) and cisplatin (P) in anthracycline-pretreated advanced breast cancer (ABC); preliminary results
11. A phase II study of Docetaxel (D) and Vinorelbine (V) in metastatic breast cancer (MBC)
12. Docetaxel + vinorelbine with concurrent G-CSF support; a phase II study in stage IV breast cancer
13. Docetaxel and vinorelbine every 14-days in patients with metastatic breast cancer after using anthracyclines. Final results
14. A phase II study of docetaxel (T) and carboplatin (CBP) as second line chemotherapy in metastatic breast cancer